Antifungal F2G Raises $60m, Sees Harmonized Route To Market

UK-based antifungal company F2G has raised $60m as it prepares a pivotal trial of its lead drug candidate for the treatment of invasive fungal infections. With both oral and IV formulations of its lead candidate and a harmonized regulatory pathway agreed with the US FDA and EMA, CEO Ian Nicholson believes a 2019 filing is achievable.

FTG has raised $60m in a series E financing round led by Sectoral Asset Management, with participation from Novo A/S, Aisling Capital and Brace Pharma Capital. Existing investors Advent Life Sciences LLP, Novartis Venture Fund, Sunstone Capital and Merifin Capital also participated.

The latest cash influx brings the total amount of venture capital raised by the firm to around £70m, Nicholson told...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip